| heart failure | 11362.654529566 |
| chronic heart failure | 519.90606666886 |
| symptoms of heart failure | 513.21411655139 |
| n engl j med | 390.00549803189 |
| heart failure hospitalization | 356.42102496814 |
| congestive heart failure | 280.57032391471 |
| coronary artery disease | 277.15825556087 |
| j am coll cardiol | 271.7851694969 |
| iv heart failure | 224.04269055375 |
| systolic heart failure | 187.10772077547 |
| heart rate | 177.54273087838 |
| severe heart failure | 171.42592868794 |
| decompensated heart failure | 164.42484855543 |
| ejection fraction | 164.27110467461 |
| incident heart failure | 163.40050263775 |
| et al | 153.3196976963 |
| management of heart failure | 147.17527658401 |
| diastolic heart failure | 147.17527658401 |
| american heart association | 143.75766327291 |
| acute decompensated heart failure | 143.51945164387 |
| new-onset heart failure | 141.21630632987 |
| heart failure society of america | 120.506594213 |
| incidence of heart failure | 118.88245834328 |
| heart disease | 115.51473789864 |
| ace inhibitors | 104.12993381006 |
| myocardial infarction | 97.141201813281 |
| symptomatic heart failure | 95.180225031078 |
| ventricular dysfunction | 91.927834917645 |
| nyha class ii | 89.843380196645 |
| advanced heart failure | 77.875396291055 |
| diagnosis of heart failure | 76.36157006205 |
| heart failure trial | 74.680896851249 |
| valsartan heart failure trial | 69.316207802652 |
| suspected heart failure | 68.030424883464 |
| clinical heart failure | 67.671396040077 |
| structural heart disease | 65.794994603193 |
| development of heart failure | 64.845532444825 |
| heart work | 61.502606079176 |
| risk factors | 56.78140354932 |
| increased risk | 55.130657644958 |
| systolic dysfunction | 53.149688412681 |
| treatment of heart failure | 52.64902149553 |
| heart failure patients | 52.488256746022 |
| history of heart failure | 49.058425528003 |
| heart failure outcomes | 48.828628936152 |
| prevention of heart failure | 48.828628936152 |
| common cause of heart failure | 46.217324350561 |
| diastolic dysfunction | 44.493513012808 |
| accf/aha stages of heart failure | 43.933256091005 |
| acute heart failure | 43.291703567625 |
| ventricular hypertrophy | 42.556750670457 |
| blood pressure | 40.912311036161 |
| ace inhibitor | 40.465445621929 |
| acute myocardial infarction | 39.157846511086 |
| valvular heart disease | 39.07778423469 |
| progression of heart failure | 38.937698145528 |
| reduced ejection fraction | 38.279943609919 |
| cardiac transplant | 38.088840897721 |
| nyha class | 37.168436488375 |
| systolic heart failure treatment | 36.624624147531 |
| clinical trial | 36.514252915594 |
| type of heart failure | 36.393324585865 |
| end-stage heart failure | 36.393324585865 |
| new heart failure | 36.393324585865 |
| chronic systolic heart failure | 36.280570898978 |
| heart failure hospitalizations | 35.304076582467 |
| heart failure information | 35.304076582467 |
| new york heart association | 35.161605961199 |
| chronic heart failure therapy | 34.119607961832 |
| heart failure exacerbations | 34.015212441732 |
| mild heart failure | 34.015212441732 |
| heart outcomes prevention evaluation | 32.550361330155 |
| overt heart failure | 32.422766222413 |
| refractory heart failure | 32.422766222413 |
| standard medical therapy | 32.220500574413 |
| comprehensive heart failure practice guideline | 30.512498229377 |
| established heart failure | 30.30410916161 |
| undiagnosed heart failure | 30.30410916161 |
| preserved ejection fraction | 29.847191914672 |
| primary symptoms of heart failure | 29.832302124903 |
| current symptoms of heart failure | 29.396302199663 |
| severe symptoms | 29.302732011878 |
| chronic congestive heart failure | 29.232377228144 |
| ventricular ejection fraction | 29.073272214158 |
| nyha class ii heart failure | 28.730557789481 |
| severe decompensated heart failure | 28.487192131714 |
| butler j | 27.817093114978 |
| functional cause of heart failure symptoms | 27.674153402284 |
| high risk | 27.565328822479 |
| severe chronic heart failure | 27.381589902864 |
| coronary disease | 27.162114335027 |
| nonischemic systolic heart failure | 27.139328065196 |
| functional class | 27.089969968019 |
| severe symptomatic heart failure | 25.624331641334 |
| advanced chronic heart failure | 25.481440613546 |
| non-ischemic systolic heart failure | 25.460562669705 |
| severe congestive heart failure | 25.289070095955 |
| renal function | 25.135581073296 |
| primary cause of heart failure | 24.870462797164 |
| stage c heart failure | 24.649903576842 |
| all-cause mortality | 24.578701598965 |
| pitt b | 23.905695622382 |
| valsartan heart failure trial investigators | 23.623333128789 |
| nyha class iii | 23.577076175429 |
| eur heart j | 23.377254482009 |
| long-term management of heart failure | 23.190179526877 |
| left ventricular systolic dysfunction | 22.710284630869 |
| ventricular pacing | 22.70333804263 |
| african american heart failure trial | 22.64064168927 |
| standard therapy | 22.62189070204 |
| left ventricular dysfunction | 22.095958211392 |
| family history of heart failure | 22.044116795314 |
| health burden of heart failure | 21.8669953659 |
| pulmonary artery pressure | 21.802122352441 |
| cardiovascular death | 21.65736770668 |
| myocardial ischemia | 21.502111138339 |
| randomized trial of patients | 21.281414946154 |
| population burden of heart failure | 21.265488388788 |
| high blood pressure | 20.387204864274 |
| borderline diastolic heart failure | 20.214544230179 |
| physical activity | 19.991995195515 |
| yusuf s | 19.817003712138 |
| different stages of heart failure | 19.759060825555 |
| african-american heart failure trial investigators | 19.74813326343 |
| early evidence of heart failure | 19.589389217353 |
| advanced end-stage heart failure | 19.500538833241 |
| clinical trials | 19.364606884933 |
| cases of incident heart failure | 19.215537915851 |
| modifiable risk factors | 19.096568395957 |
| heart catheterization | 19.078208021575 |
| cardiovascular disease | 18.95254888215 |
| heart failure incidence increases | 18.782564580814 |
| jacc heart fail | 18.673112610951 |
| treatment of preserved cardiac function heart failure | 18.550149920084 |
| palliative care | 18.44179994736 |
| total cost of heart failure | 18.265902668449 |
| nyha functional class iii heart failure patients | 18.217454040627 |
| medical therapy | 17.964918147966 |
| natural progression of heart failure | 17.882072954752 |
| emergency diagnosis of heart failure | 17.620725961188 |
| framingham heart study | 17.498080233577 |
| other risk factors | 17.278687223499 |
| heart murmur | 17.23910699358 |
| heart pumps | 17.23910699358 |
| randomized aldactone evaluation study | 17.087538022693 |
| clinical manifestations | 16.83639757978 |
| american college of cardiology/american heart association task force | 16.535658500992 |
| sinus rhythm | 16.413388798409 |
| rate control | 16.264836064977 |
| isosorbide dinitrate | 15.731731418229 |
| atrial fibrillation | 14.831171004269 |
| effect of enalapril | 14.810436756732 |
| reduced left ventricular ejection fractions | 14.67049846495 |
| clinical practice guidelines | 14.331909251528 |
| standard oral heart failure medications | 14.300957322253 |
| ventricular systolic dysfunction | 14.250752107168 |
| cardiac resynchronization-heart failure | 14.182398182435 |
| b-type natriuretic peptide | 14.104527674707 |
| seattle heart failure model | 14.084936415565 |
| heart outcomes prevention evaluation study investigators | 13.643378821151 |
| natriuretic peptide | 13.63463239761 |
| myocardial dysfunction | 13.339979404194 |
| large randomized controlled trial | 13.319992037631 |
| significant difference | 13.239003678587 |
| cardiac resynchronization | 13.127272139645 |
| randomized trial | 12.804343491775 |
| mcmurray jj | 12.728649475109 |
| symptomatic patients | 12.688455161287 |
| primary prevention | 12.638597791832 |
| weight gain | 12.358602863443 |
| pulmonary artery | 12.189889456761 |
| high-risk patients | 12.160801393263 |
| natriuretic peptide-guided therapy | 12.148130455988 |
| presence of risk factors | 12.135032696779 |
| mechanical circulatory support | 12.05693358307 |
| nonischemic cardiomyopathy | 11.988264044641 |
| svensson am | 11.741784511603 |
| ventricular function | 11.641674912519 |
| left ventricular ejection fraction | 11.525563868743 |
| asymptomatic patients | 11.500975876433 |
| functional capacity | 11.465313506452 |
| nhlbi heart failure clinical research network | 11.358108274759 |
| survival study | 11.233623397695 |
| icd implantation | 11.19016562612 |
| jessup m. stage b heart failure | 11.118430014839 |
| eplerenone post-acute myocardial infarction heart failure efficacy | 10.997210408437 |
| hospitalization rates | 10.954451150103 |
| global myocardial ischemia | 10.912809166167 |
| systolic blood pressure | 10.88520498932 |
| ventricular volume | 10.702456190343 |
| quality of life | 10.669676460234 |
| physical examination | 10.602356529148 |
| microvascular disease | 10.487221590056 |
| right heart catheterization | 10.4799301148 |
| specific causes | 10.392304845413 |
| bozkurt b | 10.392304845413 |
| trial investigators | 10.388739120117 |
| reduced risk | 10.261558002989 |
| controlled trial | 10.182919580087 |
| nyha functional classification | 10.142555229712 |
| clinical practice | 10.102415878263 |
| pulmonary disease | 10.019940278469 |
| cardiovascular mortality | 9.9312951847935 |
| inotropic agents | 9.7291971163912 |
| clinical outcomes | 9.6522804347375 |
| moderate symptoms | 9.6411410273358 |
| systolic blood pressure intervention trial | 9.6084651563334 |
| aldosterone antagonist | 9.603257618831 |
| study investigators | 9.5876942772625 |
| current guidelines | 9.5803106027242 |
| intravenous inotropic agents | 9.5374267604657 |
| acute coronary syndrome | 9.4985091341904 |
| american college of cardiology foundation | 9.3845904936053 |
| controlled trial of patients | 9.1337089660923 |
| american heart association statistics committee | 8.9787339517073 |
| coronary revascularization | 8.9720926873273 |
| cohn jn | 8.9442719099992 |
| other causes | 8.9442719099992 |
| induced coronary artery disease | 8.847853494422 |
| specific cause | 8.8186670410496 |
| disease control | 8.8186670410496 |
| circ heart fail | 8.7264615096001 |
| angiotensin receptor?neprilysin inhibitor | 8.7211839342619 |
| survival study investigators | 8.6332728113428 |
| wilson j | 8.6289073396314 |
| young j | 8.6289073396314 |
| lindenfeld j | 8.6289073396314 |
| consensus trial study group | 8.5920924788324 |
| symptomatic nyha class ii | 8.5915760184806 |
| ace inhibitor therapy | 8.5800543746011 |
| systemic disease | 8.5291344178582 |
| effect of carvedilol | 8.5242951907087 |
| krishnaswamy p | 8.4852813742386 |
| cardiovascular disease hospitalization | 8.4455351182242 |
| low cardiac output | 8.4200214932682 |
| third heart sound | 8.4078800764062 |
| initial laboratory evaluation | 8.3925789638182 |
| evaluation of patients | 8.3725700160278 |
| casey de jr | 8.2985253256109 |
| randomised trial | 8.1812469784701 |
| cardiac-resynchronization therapy | 8.1739324901763 |
| usual care | 8.1221727394757 |
| adverse changes | 8.1072009288422 |
| reduced mortality | 8.0770059874436 |
| ischemic cardiomyopathy | 7.9921760297609 |
| angiotensin-converting enzyme | 7.9774438454175 |
| lee kl | 7.8964440777149 |
| champion trial study group | 7.8789835426777 |
| 6-minute walk test | 7.845962916071 |
| haarbo j | 7.7970979610547 |
| neaton j | 7.7970979610547 |
| pogue j | 7.7970979610547 |
| emberson j | 7.7970979610547 |
| bosch j | 7.7970979610547 |
| mccord j | 7.7970979610547 |
| gong j | 7.7970979610547 |
| gallagher j | 7.7970979610547 |
| mathew j | 7.7970979610547 |
| care of patients | 7.7844093950776 |
| randomized aldactone evaluation study investigators | 7.7057858141598 |
| poor functional status | 7.5438910962342 |
| angiotensin receptor?neprilysin inhibitors | 7.5417066766768 |
| right ventricular function | 7.5395190889965 |
| clinical guidelines | 7.5352689577953 |
| implantable pulmonary artery pressure | 7.5053420380578 |
| cardiomems heart sensor | 7.490569582348 |
| left ventricular hypertrophy | 7.4659422745248 |
| cardiac resynchronization therapy | 7.461797978668 |
| acute pulmonary disease | 7.4527789849152 |
| glycemic control | 7.4448388728168 |
| randomized trial danish | 7.377854493525 |
| american college of cardiology foundation/american heart association task force | 7.3615515350663 |
| other risk factor | 7.3557314102613 |
| 20,985 patients | 7.3484692283495 |
| swedberg k | 7.3484692283495 |
| blood volume | 7.3256830029694 |
| first hospitalization | 7.3256830029694 |
| primary risk factors | 7.2867046089153 |
| inhibitor ivabradine trial | 7.2716336769238 |
| renal disease | 7.2560172494525 |
| functional class guides treatment | 7.2225756445557 |
| quality of care | 7.2217462736946 |
| observational study | 7.1407419177511 |
| zannad f | 7.1352426900163 |
| subset of patients | 7.1352426900163 |
| cardiovascular events | 7.1131176401557 |
| medical history | 7.0851677179898 |
| clinical studies | 7.0568830507494 |
| disease progression | 6.9009799013736 |
| advanced disease | 6.9009799013736 |
| volume overload | 6.8795812565008 |
| natriuretic peptide levels | 6.7807496594118 |
| loop diuretics | 6.700737917669 |
| clinical status | 6.673987930963 |
| effects of treatment | 6.6706214794855 |
| ventricular size | 6.6604914252356 |
| danish study | 6.6452091262532 |
| implantable cardioverter-defibrillator | 6.6400915182019 |
| angiotensin-receptor blockers | 6.6400915182019 |
| kazanegra r | 6.6195018392937 |
| prophylactic implantation | 6.6195018392937 |
| boineau r | 6.6195018392937 |
| latini r | 6.6195018392937 |
| outcomes of patients | 6.5934915059146 |
| range of risk factor levels | 6.558071028175 |
| american college of cardiology | 6.5412422314049 |
| effects of candesartan | 6.4474195909412 |
| usual clinical care | 6.3802363071573 |
| major risk factors | 6.3655227986524 |
| miracle icd trial | 6.3547610473256 |
| history of hospitalization | 6.3442275806434 |
| adverse effects | 6.3442275806434 |
| cannom ds | 6.3442275806434 |
| cardiac insufficiency bisoprolol study ii | 6.3179627563086 |
| multicenter insync icd randomized clinical evaluation | 6.3095633402878 |
| relative risk | 6.3086842910598 |
| lifetime risk | 6.3086842910598 |
| risk score | 6.3086842910598 |
| atherosclerosis risk | 6.3086842910598 |
| influence risk | 6.3086842910598 |
| accf/aha guideline | 6.2926925672916 |
| functional capacity of patients | 6.2273448933373 |
| left-ventricular ejection fraction | 6.2133136519014 |
| accf/aha guidelines | 6.1771812387753 |
| subjective symptoms | 6.160140576482 |
| serum digoxin levels | 6.1273116840957 |
| klein h | 6.1256286272176 |
| renal insufficiency | 6.1256286272176 |
| effect of digoxin | 6.1015588940837 |
| modification of risk factors | 6.0675163483893 |
| other patients | 6.0615465140299 |
| ventricular dyssynchrony | 6.0184333968691 |
| ventricular arrhythmias | 6.0184333968691 |
| ventricular enlargement | 6.0184333968691 |
| stevenson lw | 6 |
| shortness of breath | 6 |
| such cardiovascular risk factors | 5.9621371715169 |
| valvular disease | 5.957892135529 |
| solvd investigators | 5.9436557324017 |
| val-heft investigators | 5.9436557324017 |
| charm investigators | 5.9436557324017 |
| term gheart failure h | 5.9368741417647 |
| clinical syndrome | 5.9341076602399 |
| dietary sodium restriction | 5.9191344907092 |
| controlled clinical trials | 5.8878964084292 |
| cardiogenic shock | 5.8856619127654 |
| other mechanisms | 5.8856619127654 |
| previous myocardial infarction | 5.8653533983426 |
| other adverse effects | 5.8601559088987 |
| elevated systemic blood pressure | 5.8538734383683 |
| significant differences | 5.8259012604879 |
| oral diuretic therapy | 5.8249031191339 |
| monitoring of pressure | 5.8106700157786 |
| myocardial remodeling | 5.7991674783197 |
| myocardial structure | 5.7991674783197 |
| cardiovascular outcomes | 5.7850152170382 |
| j card fail | 5.7714994741381 |
| exercise capacity | 5.7326567532262 |
| symptomatic management | 5.7326567532262 |
| champion trial investigators | 5.717797486992 |
| harrison a | 5.7005397655436 |
| krum h | 5.7005397655436 |
| rawshani a | 5.7005397655436 |
| recognized risk factors | 5.6710361016125 |
| nonmodifiable risk factors | 5.6710361016125 |
| intensive blood pressure | 5.6586941766333 |
| low doses | 5.5663153674275 |
| packer m | 5.5663153674275 |
| rates of hyperkalemia | 5.5663153674275 |
| jessup m | 5.5663153674275 |
| important adverse effects | 5.547933582892 |
| daily pulmonary artery pressure readings | 5.5321413028549 |
| cardiac toxicity | 5.5193380421438 |
| cardiac output | 5.5193380421438 |
| nonfatal myocardial infarction | 5.4820834359262 |
| rates of hospitalization | 5.4772255750517 |
| charm-preserved trial | 5.4711295994695 |
| charm-alternative trial | 5.4711295994695 |
| cardiac pump function | 5.442323265122 |
| non-ischemic cardiomyopathy treatment evaluation | 5.438910834863 |
| symptoms of volume overload | 5.4146047111091 |
| advanced therapy | 5.3787500669746 |
| large population study | 5.3481384667782 |
| masson s | 5.3446902355676 |
| barlera s | 5.3446902355676 |
| madit-crt trial investigators | 5.3441695264733 |
| prospective randomized cumulative survival study group | 5.3249941204811 |
| gerdes am | 5.3049500053196 |
| kucharska-newton am | 5.3049500053196 |
| significant effect | 5.3049500053196 |
| emphasis-hf study group | 5.2974318574102 |
| held p | 5.26429605181 |
| jourdain p | 5.26429605181 |
| magnetic resonance imaging | 5.2414827884178 |
| myocardial sarcomere | 5.2401393526787 |
| clinical characteristics | 5.2226777991727 |
| clinical benefit | 5.2226777991727 |
| clinical assessment | 5.2226777991727 |
| ventricular noncompaction cardiomyopathy results | 5.200849059796 |
| optimal medical therapy | 5.1893987221281 |
| mild symptoms | 5.1800401282227 |
| functional status | 5.1800401282227 |
| blood tests | 5.1800401282227 |
| weight monitoring | 5.1800401282227 |
| hypomagnesemia increase risk | 5.1660198496359 |
| sudden death | 5.1510191538028 |
| cardiac muscle | 5.1363228010461 |
| cardiac structure | 5.1363228010461 |
| digoxin dose | 5.0914597900437 |
| ventricular dysfunction delays onset | 5.0761464007087 |
| left-ventricular systolic function | 5.0719730249202 |
| multinational study investigators | 5.0657970191009 |
| multicenter automatic defibrillator implantation trial ii investigators | 5.0514818398486 |
| elderly study | 5.0492670327448 |
| effects of enalapril | 5.0453784915223 |
| maladaptive ventricular hypertrophy | 5.0063266198115 |
| enalapril group | 4.9737947036147 |
| high risk of re-admission | 4.9241689779833 |
| patient's clinical status | 4.9027522910779 |
| randomised trial of losartan | 4.8760319739572 |
| quality measures | 4.8645985581956 |
| fluid restriction | 4.8645985581956 |
| therapy changes | 4.8602493374348 |
| drug therapy | 4.8602493374348 |
| randomised placebo-controlled study | 4.8490562872798 |
| increase exercise capacity | 4.8465663976689 |
| ace inhibitor ramipril | 4.8409406455445 |
| practice guidelines | 4.8339055525626 |
| diabetes care | 4.8294728055328 |
| independent risk factor | 4.8284476525076 |
| absence of symptoms | 4.8205705136679 |
| loop diuretic | 4.8205705136679 |
| refractory symptoms | 4.8205705136679 |
| pressure overload | 4.8026164940938 |
| other factors | 4.7867398586908 |
| sprint research study group | 4.7637250806784 |
| disease process | 4.7381372205376 |
| reduced diastolic | 4.7381372205376 |
| lung disease | 4.7381372205376 |
| clinical suggestions | 4.7192221235411 |
| clinical suspicion | 4.7192221235411 |
| african american patients | 4.7170518987602 |
| large double-blind trial | 4.6980201586465 |
| tognoni g | 4.6806946386414 |
| ischemic stroke | 4.6806946386414 |
| pulmonary causes of exercise limitation | 4.6806946386414 |
| sudden cardiac death | 4.6575419678526 |
| cardiac sarcoidosis | 4.6411915742122 |
| cardiac involvement | 4.6411915742122 |
| cardiac workload | 4.6411915742122 |
| cardiac valves | 4.6411915742122 |
| cardiac amyloidosis | 4.6411915742122 |
| cause of death | 4.6361821858297 |
| stars-bnp multicenter study | 4.6220442888931 |
| mild patients hospitalization | 4.6196709652247 |
| chronic atrial fibrillation | 4.6132323629156 |
| association of serum digoxin concentration | 4.5916055846449 |
| patient's nyha | 4.5825756949558 |
| k?ber l | 4.5590141139096 |
| effects of valsartan | 4.5590141139096 |
| combination of ace inhibitors | 4.5582562960338 |
| coronary angiography | 4.4860463436637 |
| metoprolol cr/xl randomised intervention trial | 4.4287921839498 |
| diabetes mellitus | 4.4267276788013 |
| inefficient ventricular contractile function | 4.4248034309981 |
| family history of cardiomyopathy | 4.4088173933227 |
| initial evaluation | 4.3679267425564 |
| prospective clinical trials | 4.3678557314809 |
| bnp levels | 4.3558771746929 |
| severity of symptoms | 4.3558771746929 |
| oral diuretic dose | 4.3440506352097 |
| other measures | 4.3253077270721 |
| american college of physicians | 4.3231140296575 |
| left-ventricular dysfunction | 4.2813902858562 |
| conduction abnormalities | 4.2813902858562 |
| givertz mm | 4.2813902858562 |
| maladaptive ventricular remodeling | 4.2513258303959 |
| prophylactic icd implantation | 4.2484406376281 |
| other important guidelines | 4.2448203141176 |
| right ventricular free wall | 4.2425598510497 |
| composite outcome | 4.2294850537623 |
| daubert jp | 4.2294850537623 |
| plasma digoxin levels | 4.2227675591121 |
| peripartum cardiomyopathy | 4.1824461364775 |
| other systemic disorders | 4.1689486953466 |
| cooperative north scandinavian enalapril survival study | 4.1683924274728 |
| oral furosemide therapy | 4.1633714773242 |
| recent observational study | 4.1623049031538 |
| prophylactic icd | 4.1408245796559 |
| objective measures of disease status | 4.1301657152851 |
| sinus rate | 4.1195342878142 |
| oxygen-rich blood | 4.1195342878142 |
| blood flow | 4.1195342878142 |
| blood counts | 4.1195342878142 |
| reduced rates | 4.090623489235 |
| Ã -blocker therapy | 4.0869662450882 |
| first-line therapy | 4.0869662450882 |
| appropriate therapy | 4.0869662450882 |
| evaluation of losartan | 4.0648138508249 |
| other important disorders | 4.0632051688874 |
| routine care | 4.0610863697379 |
| specific clinical indication | 4.0577694145156 |
| exercise training | 4.0536004644211 |
| role of palliative care | 4.0300296715324 |
| maisel as | 4 |
| gbridge therapy h | 3.9993486932656 |
| pressure-guided management of patients | 3.9654064565002 |
| serum levels of electrolytes | 3.9468319327726 |
| moss aj | 3.9359793425309 |
| staging system | 3.9359793425309 |
| ezekowitz ja | 3.9359793425309 |
| defibrillator implantation | 3.9359793425309 |
| fluid retention | 3.9359793425309 |
| patient information | 3.9359793425309 |
| controlled studies | 3.9359793425309 |
| gventricular dysfunction h | 3.9320768183025 |
| effect of diuretics | 3.8985489805273 |
| left bundle branch block | 3.8735854825302 |
| adverse events | 3.8729833462074 |
| pulmonary capillary wedge pressure | 3.8536671042695 |
| arni treatment | 3.8512851068431 |
| goal of treatment | 3.8512851068431 |
| early treatment | 3.8512851068431 |
| potential adverse effects | 3.8467222990467 |
| intolerable adverse effects | 3.8467222990467 |
| continuous intravenous inotropic agents | 3.8375885893579 |
| carvedilol post-infarct survival control | 3.8375885893579 |
| lo studio della streptochinasi nell finfarto miocardico-heart failure trial | 3.8349221943338 |
| laboratory evidence | 3.8067540958393 |
| peripheral vascular disease | 3.8027429028336 |
| houston-miller n | 3.7976578442319 |
| kagiyama n | 3.7976578442319 |
| freemantle n | 3.7976578442319 |
| heterogeneous study populations | 3.7817049765835 |
| ivabradine group | 3.7792667089114 |
| basic palliative care | 3.7666884513457 |
| palliative care addresses | 3.7666884513457 |
| aha stage c | 3.7578442412245 |
| specific type of cardiomyopathy | 3.7439265731403 |
| other treatment decisions | 3.7430197238696 |
| patient's daily weight | 3.7288210710016 |
| hall wj | 3.7224194364084 |
| qrs duration | 3.7224194364084 |
| bauman jg | 3.7224194364084 |
| muscular dystrophy | 3.7224194364084 |
| abraham wt | 3.7224194364084 |
| larson mg | 3.7224194364084 |
| pfeffer ma | 3.7224194364084 |
| incessant tachycardia | 3.7224194364084 |
| yancy cw | 3.7224194364084 |
| bourge rc | 3.7224194364084 |
| intravenous loop diuretics | 3.719046769829 |
| global mortality | 3.7126875376323 |
| adequate doses of ace inhibitors | 3.7098517435797 |
| population-based reykjavik study | 3.708192102729 |
| only therapy | 3.6929908877475 |
| ordinary physical activity | 3.6830484346607 |
| invasive evaluation | 3.6729739399065 |
| safety of exercise training | 3.6666352749723 |
| advanced stages | 3.6628415014847 |
| b-type natriuretic peptide assay | 3.6628415014847 |
| supervised exercise | 3.6628415014847 |
| a1c levels | 3.6628415014847 |
| other noninvasive imaging | 3.6590516533172 |
| effect of metoprolol cr/xl | 3.6529276674218 |
| european society of cardiology | 3.6467519140054 |
| direct myocardial toxin?it | 3.6231148419824 |
| increased mortality | 3.6161715709604 |
| regional dysfunction | 3.6002057436785 |
| sodium restriction | 3.6002057436785 |
| digoxin toxicity | 3.6002057436785 |
| serum level | 3.6002057436785 |
| controlled trials | 3.6002057436785 |
| inhibitor ramipril | 3.5840246342157 |
| angiotensin-converting-enzyme inhibitor | 3.5840246342157 |
| variety of patients | 3.5676213450082 |
| arrhythmogenic right ventricular dysplasia | 3.567553370247 |
| elevated total cholesterol levels | 3.5620857880302 |
| health care costs | 3.561271038656 |
| cardiovascular system | 3.5565588200778 |
| volume status | 3.5565588200778 |
| clinical slide set | 3.5447880909253 |
| ability of icd implantation | 3.5376050502214 |
| danish investigators | 3.5341188430494 |
| renal excretion of digoxin | 3.503082197055 |
| other medications | 3.4996355115806 |
| other à -blockers | 3.4996355115806 |
| other lifestyle changes | 3.4877505632064 |
| miracle icd | 3.4820045452271 |
| appropriate serum level of digoxin | 3.473041544387 |
| hemodynamically significant ventricular septal defects | 3.4683547086532 |
| felker gm | 3.4641016151377 |
| cigarette smoking | 3.4641016151377 |
| benjamin ej | 3.4641016151377 |
| granger cb | 3.4641016151377 |
| brown mw | 3.4641016151377 |
| family history | 3.4641016151377 |
| end-organ hypoperfusion | 3.4641016151377 |
| davis ce | 3.4641016151377 |
| few days | 3.4641016151377 |
| stable weight | 3.4641016151377 |
| united states | 3.4641016151377 |
| hiv infection | 3.4641016151377 |
| d fagostino r jr | 3.4519247197843 |
| first-line drug therapy | 3.4458199066465 |
| nondiabetic control group | 3.4312578792284 |
| other relevant pqrs quality measures | 3.4278736200193 |
| spironolactone group | 3.4149529703483 |
| collaborative care | 3.4149529703483 |
| guided care | 3.4149529703483 |
| decrease hospitalization | 3.4086580994025 |
| bundle branch block | 3.3967626591299 |
| effect of spironolactone | 3.3895612242702 |
| trabeculated myocardial architecture | 3.3863633634254 |
| aha stage | 3.3635856610149 |
| use of bnp | 3.3635856610149 |
| prophylactic defibrillator implantation | 3.3604214537127 |
| other performance measures | 3.3446807651574 |
| other tests | 3.3437015248821 |
| meta-analysis global group | 3.3285607270274 |
| cardiopulmonary exercise test | 3.3244690547396 |
| smith r | 3.3097509196469 |
| natriuretic peptides | 3.3097509196469 |
| genetic disorders | 3.3097509196469 |
| careful monitoring of serum potassium levels | 3.2957569692557 |
| severe cardiogenic shock | 3.2598444275496 |
| current measures | 3.2531531233956 |
| time-to-furosemide treatment | 3.2385318404644 |
| hospital admission rate | 3.2377408137211 |
| angiotensin-converting enzyme inhibitors | 3.2368032890054 |
| atrial arrhythmia | 3.2237097954706 |
| hospitalized patients | 3.2237097954706 |
| selected patients | 3.2237097954706 |
| natural history | 3.2237097954706 |
| elevated levels of low-density lipoprotein cholesterol | 3.2113286293254 |
| low high-density lipoprotein cholesterol levels | 3.2113286293254 |
| detrimental effect of sodium restriction | 3.2033666669598 |
| functional mitral regurgitation | 3.2031009475288 |
| cardiopulmonary exercise testing | 3.2031009475288 |
| obesity-related cardiomyopathy | 3.1779718278113 |
| dilated cardiomyopathy | 3.1779718278113 |
| tachycardia-induced cardiomyopathy | 3.1779718278113 |
| diabetic cardiomyopathy | 3.1779718278113 |
| eplerenone group | 3.1779718278113 |
| hypertrophic cardiomyopathy | 3.1779718278113 |
| ordinary physical activity results | 3.1616447614742 |
| prediction of survival | 3.1463462836458 |
| expected survival | 3.1463462836458 |
| survival advantage | 3.1463462836458 |
| meaningful survival | 3.1463462836458 |
| noninvasive imaging | 3.1301691601466 |
| long-term use | 3.1301691601466 |
| aborted cardiac arrest | 3.1231391134797 |
| smith al | 3.1054227990715 |
| structured cardiac rehabilitation program | 3.0918884056739 |
| high doses | 3.080070288241 |
| large multicenter | 3.080070288241 |
| nt-probnp levels | 3.080070288241 |
| thiazide diuretic | 3.080070288241 |
| electrolyte levels | 3.080070288241 |
| current aha guidelines | 3.0668124740328 |
| yancy c | 3.0628143136088 |
| other genetic disorders of iron metabolism | 3.0600833060707 |
| different types of care | 3.0569032462135 |
| elevated jugular venous pressure | 3.0400841363597 |
| systemic disorder | 3.0274001040351 |
| practice improvement | 3.0274001040351 |
| systemic diseases | 3.0274001040351 |
| iron overload | 3.0274001040351 |
| daily weight checks | 3.0261714988458 |
| iervasi g. thyroid replacement therapy | 3.0061164174793 |
| natriuretic peptide-based screening | 2.9937951655239 |
| observational studies | 2.9906975624424 |
| doukky r | 2.9906975624424 |
| segal r | 2.9906975624424 |
| quigg r | 2.9906975624424 |
| comenzo r | 2.9906975624424 |
| quality indicators | 2.9906975624424 |
| marchioli r | 2.9906975624424 |
| davies r | 2.9906975624424 |
| lieberman r | 2.9906975624424 |
| cody r | 2.9906975624424 |
| deo r | 2.9906975624424 |
| cremo r | 2.9906975624424 |
| amirnovin r | 2.9906975624424 |
| physical activities | 2.9718278662008 |
| physical exam | 2.9718278662008 |
| physical therapists | 2.9718278662008 |
| predictors of mortality | 2.9525917237372 |
| laboratory tests | 2.9428309563827 |
| such reversible cardiac conditions | 2.9390867394432 |
| hospital readmission rates | 2.9355985352441 |
| long-term inotropic infusion | 2.9279034960725 |
| specific structural abnormalities | 2.9279034960725 |
| physician quality reporting system | 2.9278526754426 |
| riegel b | 2.9129506302439 |
| history of angioedema | 2.9129506302439 |
| end-of-life management | 2.9129506302439 |
| olofsson b | 2.9129506302439 |
| increased bnp | 2.9129506302439 |
| levin b | 2.9129506302439 |
| eliasson b | 2.9129506302439 |
| symptom management | 2.9129506302439 |
| roniker b | 2.9129506302439 |
| significant data | 2.9129506302439 |
| wilkoff b | 2.9129506302439 |
| claggett b | 2.9129506302439 |
| diastolic relaxation | 2.9129506302439 |
| reduced hospitalizations | 2.8925076085191 |
| unexplained weight gain | 2.8844991406148 |
| angiotensin-receptor blocker valsartan | 2.8844991406148 |
| intensive hypertension control | 2.8844991406148 |
| lot of weight gain | 2.8844991406148 |
| angiotensin-converting-enzyme inhibitors | 2.882121417102 |
| acute exacerbations | 2.8716217110259 |
| placebo group | 2.8716217110259 |
| sacubitril?valsartan group | 2.8716217110259 |
| epicardial coronary arteries | 2.8536385282275 |
| thyroid-stimulating hormone levels | 2.8536385282275 |
| maggioni a | 2.8502698827718 |
| left ventricle | 2.8502698827718 |
| outpatient dose | 2.8284271247462 |
| routine use | 2.8284271247462 |
| ordinary activity | 2.8284271247462 |
| selective aldosterone blocker | 2.8210130123402 |
| combination of isosorbide dinitrate | 2.8077989890847 |
| taylor al | 2.8060662632967 |
| symptomatic bradycardia | 2.7831576837137 |
| diuretic effectiveness | 2.7831576837137 |
| lee ds | 2.7831576837137 |
| diuretic strategies | 2.7831576837137 |
| diuretic adjustments | 2.7831576837137 |
| Ã -blockers carvedilol | 2.7831576837137 |
| biomarker intensified treatment | 2.7578805125536 |
| overall mortality | 2.7476962050545 |
| structured aerobic exercise program | 2.746743631666 |
| liver function | 2.7355647997348 |
| rosengren a. glycaemic control | 2.7285232036427 |
| levy d | 2.7108060108295 |
| atrial abnormality | 2.7108060108295 |
| important characteristics | 2.7108060108295 |
| important organs | 2.7108060108295 |
| long-term safety | 2.7108060108295 |
| wide range of causes | 2.6960123091946 |
| nonvalvular atrial fibrillation | 2.6889452937027 |
| shift investigators | 2.6853496142827 |
| topcat investigators | 2.6853496142827 |
| paradigm-hf investigators | 2.6853496142827 |
| warcef investigators | 2.6853496142827 |
| gissi-hf investigators | 2.6853496142827 |
| hf-action investigators | 2.6853496142827 |
| hope investigators | 2.6853496142827 |
| acute dyspnea | 2.6723451177838 |
| formal exercise programs | 2.66716827534 |
| other shunts | 2.6591479484725 |
| le helloco a | 2.6571971456127 |
| elkayam u. peripartum cardiomyopathy | 2.6521704180372 |
| v-heft va cooperative studies group | 2.6379831394264 |
| tolerated dose | 2.632148025905 |
| significant reductions | 2.632148025905 |
| last dose | 2.632148025905 |
| sodium intake | 2.632148025905 |
| significant reduction | 2.632148025905 |
| angiotensin-receptor blocker | 2.632148025905 |
| elevated bnp | 2.632148025905 |
| current medications | 2.632148025905 |
| ann intern med | 2.6207413942089 |
| selective aldosterone antagonist | 2.6084654714896 |
| several consensus guidelines | 2.6043085235871 |
| heterogeneous group of outpatients | 2.5958936998277 |
| hemodynamic monitoring | 2.5900200641113 |
| cushman m | 2.5900200641113 |
| baggett c | 2.5755095769014 |
| avezum a | 2.5755095769014 |
| perez a | 2.5755095769014 |
| rapezzi c | 2.5755095769014 |
| chavelas c | 2.5755095769014 |
| kiran a | 2.5755095769014 |
| dan a | 2.5755095769014 |
| barth c | 2.5755095769014 |
| dyer a | 2.5755095769014 |
| yilmaz a | 2.5755095769014 |
| shi h | 2.5755095769014 |
| castaigne a | 2.5755095769014 |
| mangla a | 2.5755095769014 |
| henrick a | 2.5755095769014 |
| dubost-brama a | 2.5755095769014 |
| laupacis a | 2.5755095769014 |
| kopp a | 2.5755095769014 |
| ukena c | 2.5755095769014 |
| avogaro a | 2.5755095769014 |
| conlon c | 2.5755095769014 |
| kadish a | 2.5755095769014 |
| glomerular filtration rate | 2.5697965868507 |
| tolerated dose of à -blockers | 2.5697965868507 |
| intravenous bolus | 2.5457298950218 |
| definitive evidence | 2.5457298950218 |
| strong evidence | 2.5457298950218 |
| aldosterone antagonists | 2.5457298950218 |
| causative factors | 2.5457298950218 |
| digitalis investigation group | 2.5454319088428 |
| short-term symptomatic benefits | 2.5423029068338 |
| used loop diuretics | 2.5132368765511 |
| parasuraman s. glycemic control | 2.5020668097181 |
| in-hospital mortality | 2.4828237961984 |
| physician quality reporting initiative?that clinicians | 2.4754341287137 |
| overt cardiogenic shock | 2.4662120743305 |
| rapid b-natriuretic peptide assay | 2.4494897427832 |
| advanced therapies | 2.4494897427832 |
| primary outcome | 2.4494897427832 |
| kavalieratos d | 2.4494897427832 |
| logeart d | 2.4494897427832 |
| same population | 2.4494897427832 |
| lifestyle modifications | 2.4494897427832 |
| aguilar d | 2.4494897427832 |
| johnstone d | 2.4494897427832 |
| ettehad d | 2.4494897427832 |
| mozaffarian d | 2.4494897427832 |
| gras d | 2.4494897427832 |
| valvular abnormalities | 2.4322992790978 |
| joshua-gotlib s | 2.4147364027664 |
| franz?n s | 2.4147364027664 |
| kuroda s | 2.4147364027664 |
| homma s | 2.4147364027664 |
| ziesche s | 2.4147364027664 |
| gudbj?rnsdottir s | 2.4147364027664 |
| non?left bundle branch block pattern | 2.3924623977026 |
| carson p | 2.3784142300054 |
| clopton p | 2.3784142300054 |
| severe comorbidities | 2.3784142300054 |
| maximum dose | 2.3784142300054 |
| beyne p | 2.3784142300054 |
| severe signs | 2.3784142300054 |
| sleight p | 2.3784142300054 |
| gueffet p | 2.3784142300054 |
| use age | 2.3784142300054 |
| elliott p | 2.3784142300054 |
| mohacsi p | 2.3784142300054 |
| afterload-reducing agents | 2.3784142300054 |
| duc p | 2.3784142300054 |
| dennison himmelfarb c | 2.3672935308725 |
| terms gcardiomyopathy h | 2.3672935308725 |
| dei cas a | 2.3672935308725 |
| systemic lupus erythematosus | 2.3490100793233 |
| continuous intravenous administration | 2.3490100793233 |
| multicenter guide-it | 2.3403473193207 |
| komajda m | 2.3403473193207 |
| lenski m | 2.3403473193207 |
| miftaraj m | 2.3403473193207 |
| diagnostic tests | 2.3403473193207 |
| lind m | 2.3403473193207 |
| b?hm m | 2.3403473193207 |
| fiuzat m | 2.3403473193207 |
| olsson m | 2.3403473193207 |
| Ã -blocker carvedilol | 2.3403473193207 |
| ledwidge m | 2.3403473193207 |
| semigran m | 2.3403473193207 |
| electrocardiographic monitoring | 2.3403473193207 |
| hospital-level 30-day mortality | 2.3101522238684 |
| robust predictor of mortality | 2.3101522238684 |
| oral anticoagulants | 2.3003266337912 |
| nma/pcna guideline | 2.3003266337912 |
| oral torsemide | 2.3003266337912 |
| patient's outpatient | 2.3003266337912 |
| guiding evidence | 2.3003266337912 |
| conflicting evidence | 2.3003266337912 |
| optimal therapeutic range | 2.2894284851067 |
| replacement device | 2.2795070569548 |
| maisel a. utility | 2.2449240966188 |
| hood wb jr | 2.2390395117024 |
| several medications | 2.2133638394006 |
| subjective assessment | 2.2133638394006 |
| modification of hypertension | 2.2133638394006 |
| martinez f | 2.2133638394006 |
| healthcare research | 2.2133638394006 |
| 2-lb increase | 2.2133638394006 |
| avery e | 2.2133638394006 |
| 5-lb increase | 2.2133638394006 |
| diverse range | 2.2133638394006 |
| impact of diabetes | 2.2133638394006 |
| general population | 2.2133638394006 |
| patient's subjective experience | 2.1955146386099 |
| stroke statistics subcommittee | 2.1822472719434 |
| role of lifestyle modifications | 2.1822472719434 |
| deswal a. relationship of hemoglobin | 2.1810154653305 |
| nonsudden death | 2.165736770668 |
| hemodynamic overload | 2.1406951429281 |
| thiazide diuretics | 2.1406951429281 |
| tobacco use screening | 2.1398263878673 |
| many genetic cardiomyopathies | 2.1398263878673 |
| alternative imaging methods | 2.1398263878673 |
| ojamaa k. thyroid hormone | 2.1351847961967 |
| serious health condition | 2.1169328630255 |
| thorgeirsson g | 2.1147425268811 |
| thabut g | 2.1147425268811 |
| meurers g | 2.1147425268811 |
| johnson g | 2.1147425268811 |
| dagenais g | 2.1147425268811 |
| jondeau g | 2.1147425268811 |
| ginn g | 2.1147425268811 |
| noninvasive computed tomographic angiography | 2.1039790110173 |
| author thanks lee r. goldberg | 2.0827594879848 |
| effective gsliding h regimen | 2.0812192439376 |
| djousse l | 2.0597671439071 |
| hood wb | 2.0597671439071 |
| tavazzi l | 2.0597671439071 |
| long-term benefit | 2.0597671439071 |
| damman k | 2.0597671439071 |
| rapid measurement | 2.0597671439071 |
| matsushita k | 2.0597671439071 |
| primary prophylaxis | 2.0597671439071 |
| lenert l | 2.0597671439071 |
| ramasubbu k | 2.0597671439071 |
| malmberg k | 2.0597671439071 |
| additional medications | 2.0597671439071 |
| kappenberger l | 2.0597671439071 |
| angelici l | 2.0597671439071 |
| ferdinand k | 2.0597671439071 |
| fibrofatty replacement | 2.0597671439071 |
| videb?k l | 2.0597671439071 |
| 2-dimensional doppler echocardiography | 2.0396489026555 |
| two-dimensional doppler echocardiography | 2.0396489026555 |
| additional diagnostic testing | 2.0396489026555 |
| prognostic value of changes | 2.0396489026555 |
| raimondi e | 2 |
| korup e | 2 |
| chemotherapeutic agents trastuzumab | 2 |
| total distance | 2 |
| tallon e | 2 |
| funck f | 2 |
| suspected cases | 2 |
| long-standing untreated hypertension | 2 |
| daubert jc | 2 |
| mahfoud f | 2 |
| million persons | 2 |
| 7.5 mg | 2 |
| beauvais f | 2 |
| donal e | 2 |
| million hospital discharges | 2 |
| hemoglobin a1c | 2 |
| erdmann e | 2 |
| o fconnell e | 2 |
| prospective comparison of arni | 2 |
| home health staff | 1.9786024464679 |
| lindenfeld ja | 1.9679896712654 |
| prognostic information | 1.9679896712654 |
| high-risk populations | 1.9679896712654 |
| combination of hydralazine | 1.9679896712654 |
| downloadable guideline algorithm | 1.9559811771959 |
| wall-motion abnormalities | 1.9343364202677 |
| thune jj | 1.9343364202677 |
| active ischemia | 1.9343364202677 |
| mamdani mm | 1.9343364202677 |
| redfield mm | 1.9343364202677 |
| patient's circumstances | 1.9343364202677 |
| teerlink jr | 1.9343364202677 |
| scheinman mm | 1.9343364202677 |
| glucose abnormalities | 1.9343364202677 |
| colvin mm | 1.9343364202677 |
| excess iron deposition | 1.9063685859939 |
| long-acting metoprolol succinate | 1.9063685859939 |
| implantable cardioversion defibrillation | 1.9063685859939 |
| sustained efficacy | 1.8612097182042 |
| goldberg lr | 1.8612097182042 |
| alcohol consumption | 1.8612097182042 |
| vago t | 1.8612097182042 |
| efficacy of icds | 1.8612097182042 |
| many areas | 1.8612097182042 |
| absence of arrhythmia | 1.8612097182042 |
| remme wj | 1.8612097182042 |
| continuous infusion | 1.8612097182042 |
| social support | 1.8612097182042 |
| direct toxicity | 1.8612097182042 |
| new agent | 1.8612097182042 |
| first calls | 1.8612097182042 |
| hardarson t | 1.8612097182042 |
| routine anticoagulation | 1.8612097182042 |
| definitive therapies | 1.8612097182042 |
| major hemorrhage | 1.8612097182042 |
| aspelund t | 1.8612097182042 |
| yamaguchi t | 1.8612097182042 |
| objective predictors | 1.8612097182042 |
| callender t | 1.8612097182042 |
| common precursor molecule | 1.8493111942973 |
| composite end point | 1.8493111942973 |
| regular measurement of electrolytes | 1.8171205928321 |
| improved safety profiles | 1.8171205928321 |
| van veldhuisen dj | 1.7817974362807 |
| early postpartum period | 1.7817974362807 |
| complete follow-up results | 1.7817974362807 |
| several regulatory agencies | 1.7817974362807 |
| review of animal models | 1.7817974362807 |
| composite of time | 1.7782794100389 |
| common questions | 1.7782794100389 |
| preventable syndrome | 1.7782794100389 |
| frequent hospitalizations | 1.7782794100389 |
| combination of sacubitril | 1.7782794100389 |
| heart-failure events | 1.7782794100389 |
| recurrent hospitalizations | 1.7782794100389 |
| neyra ja | 1.7782794100389 |
| curtis jp | 1.7782794100389 |
| biventricular pacing | 1.7782794100389 |
| boehmer jp | 1.7782794100389 |
| coats aj | 1.7782794100389 |
| cowley aj | 1.7782794100389 |
| peripheral edema | 1.7320508075689 |
| same benefits | 1.7320508075689 |
| strong muscle | 1.7320508075689 |
| collins kj | 1.7320508075689 |
| cushman wc | 1.7320508075689 |
| aortic regurgitation | 1.7320508075689 |
| maggioni ap | 1.7320508075689 |
| levy wc | 1.7320508075689 |
| remme w | 1.7320508075689 |
| wang y | 1.7320508075689 |
| stable outpatients | 1.7320508075689 |
| peak oxygen consumption | 1.6983813295649 |
| paroxysmal nocturnal dyspnea | 1.6983813295649 |
| last trimester of pregnancy | 1.6983813295649 |
| giant cell myocarditis | 1.6983813295649 |
| shantsila e. anticoagulation | 1.6983813295649 |
| katus ha | 1.6817928305074 |
| franzosi mg | 1.6817928305074 |
| whellan dj | 1.6817928305074 |
| evans jc | 1.6817928305074 |
| sound waves | 1.6817928305074 |
| freudenberger rs | 1.6817928305074 |
| one meta-analysis | 1.6817928305074 |
| stress testing | 1.6817928305074 |
| increases regression | 1.6817928305074 |
| wilber dj | 1.6817928305074 |
| muscular dystrophies | 1.6817928305074 |
| white persons | 1.6817928305074 |
| episodic arrhythmia | 1.6817928305074 |
| ellis sj | 1.6817928305074 |
| desai as | 1.6817928305074 |
| packer dl | 1.6817928305074 |
| qrs prolongation | 1.6817928305074 |
| nielsen jc | 1.6817928305074 |
| tycon le | 1.6817928305074 |
| systematic review | 1.6817928305074 |
| rare disorder | 1.6817928305074 |
| klein hu | 1.6817928305074 |
| major problem | 1.6817928305074 |
| beanlands rs | 1.6817928305074 |
| unpredictable exacerbations | 1.6817928305074 |
| elimination of tachycardia | 1.6817928305074 |
| slight limitation | 1.6817928305074 |
| poor prognosis | 1.6817928305074 |
| many parts | 1.6817928305074 |
| black persons | 1.6817928305074 |
| rheumatologic diseases | 1.6817928305074 |
| ha ac | 1.6817928305074 |
| cleland jg | 1.6817928305074 |
| marked limitation | 1.6817928305074 |
| wall thickness | 1.6817928305074 |
| serial echocardiography | 1.6817928305074 |
| enrollment goal | 1.6817928305074 |
| drink alcohol | 1.6817928305074 |
| heritable disorder | 1.6817928305074 |
| vasan rs | 1.6817928305074 |
| african americans | 1.6817928305074 |
| ambrosius wt | 1.6817928305074 |
| cochrane database syst rev | 1.6817928305074 |
| wood ma | 1.6817928305074 |
| dietary recommendations | 1.6817928305074 |
| million people | 1.6817928305074 |
| keteyian sj | 1.6817928305074 |
| select therapies | 1.6817928305074 |
| ellison rc | 1.6817928305074 |
| inflammatory diseases | 1.6817928305074 |
| suitable alternative | 1.6817928305074 |
| pocock sj | 1.6817928305074 |
| insoluble fibrillar proteins | 1.5874010519682 |
| myocyte adipose accumulation | 1.5874010519682 |
| autosomal dominant mutations | 1.5874010519682 |
| complex psychosocial issues | 1.5874010519682 |
| emdin ca | 1.5650845800733 |
| fitzpatrick ap | 1.5650845800733 |
| low-sodium diet | 1.5650845800733 |
| n-terminal pro?b | 1.5650845800733 |
| lower-extremity edema | 1.5650845800733 |
| n-terminal pro-brain | 1.5650845800733 |
| das sr | 1.5650845800733 |
| rathore ss | 1.5650845800733 |
| bristow mr | 1.5650845800733 |
| anstrom kj | 1.5650845800733 |
| former condition | 1.5650845800733 |
| avery cl | 1.5650845800733 |
| collins sp | 1.5650845800733 |
| decrease afterload | 1.5650845800733 |
| jensen dn | 1.5650845800733 |
| audrey wu | 1.5650845800733 |
| hollander je | 1.5650845800733 |
| costanzo mr | 1.5650845800733 |
| nery pb | 1.5650845800733 |
| khan ss | 1.5650845800733 |
| gudnason v | 1.5650845800733 |
| ariti ca | 1.5650845800733 |
| dr. wu | 1.5650845800733 |
| shinbane js | 1.5650845800733 |
| loehr lr | 1.5650845800733 |
| wang tj | 1.5650845800733 |
| second calls | 1.5650845800733 |
| professional roles | 1.5650845800733 |
| nowak rm | 1.5650845800733 |
| matsue y | 1.5650845800733 |
| emergency department | 1.5650845800733 |
| developed areas | 1.5650845800733 |
| anderson kp | 1.5650845800733 |
| rizkala ar | 1.5650845800733 |
| juurlink dn | 1.5650845800733 |
| ann arbor | 1.5650845800733 |
| nonpharmacologic interventions | 1.5650845800733 |
| specialized interventions | 1.5650845800733 |
| cavity size | 1.5650845800733 |
| leon ar | 1.5650845800733 |
| short-term basis | 1.5650845800733 |
| borer js | 1.5650845800733 |
| carey rm | 1.5650845800733 |
| previous version | 1.5650845800733 |
| enough data | 1.5650845800733 |
| goldsmith sr | 1.5650845800733 |
| hereditary hemochromatosis | 1.5650845800733 |
| intracerebral hemorrhage | 1.5650845800733 |
| overall frailty | 1.5650845800733 |
| variety of antigens | 1.5650845800733 |
| intracardiac device | 1.5650845800733 |
| impact of obesity | 1.5650845800733 |
| wilson pw | 1.5650845800733 |
| nutritional supplements | 1.5650845800733 |
| hypersensitivity myocarditis | 1.5650845800733 |
| poole je | 1.5650845800733 |
| hereditary anemias | 1.5650845800733 |
| bekelman db | 1.5650845800733 |
| aortic stenosis | 1.5650845800733 |
| zareba w | 1.5650845800733 |
| ibrahim z | 1.5650845800733 |
| young jb | 1.5650845800733 |
| mark db | 1.5650845800733 |
| compared hydralazine | 1.5650845800733 |
| plasma brain | 1.5650845800733 |
| low-salt diet | 1.5650845800733 |
| anderson sg | 1.5650845800733 |
| various organs | 1.5650845800733 |
| nutritional deficiencies | 1.5650845800733 |
| arany z | 1.5650845800733 |
| martinez fa | 1.5650845800733 |
| professional organizations | 1.5650845800733 |
| adamson pb | 1.5650845800733 |
| kutyifa v | 1.5650845800733 |
| allergic reaction | 1.4142135623731 |
| michelson el | 1.4142135623731 |
| bonow ro | 1.4142135623731 |
| vision disturbances | 1.4142135623731 |
| leip ep | 1.4142135623731 |
| gottlieb so | 1.4142135623731 |
| cropp ab | 1.4142135623731 |
| cool extremities | 1.4142135623731 |
| sinoatrial node | 1.4142135623731 |
| walsh cr | 1.4142135623731 |
| painful gynecomastia | 1.4142135623731 |
| krumholz hm | 1.4142135623731 |
| arnold jm | 1.4142135623731 |
| urgent-care setting | 1.4142135623731 |
| unrealistic expectations | 1.4142135623731 |
| medicaid services | 1.4142135623731 |
| fowler mb | 1.4142135623731 |
| angiotensin-neprilysin inhibition | 1.4142135623731 |
| mayo clinic | 1.4142135623731 |
| congenital lesions | 1.4142135623731 |
| aronow ws | 1.4142135623731 |
| bates jt | 1.4142135623731 |
| painless procedure | 1.4142135623731 |
| past decade | 1.4142135623731 |
| estes na | 1.4142135623731 |
| collado fm | 1.4142135623731 |
| zhang zm | 1.4142135623731 |
| expert opinion | 1.4142135623731 |
| chiuve se | 1.4142135623731 |
| heavy toll | 1.4142135623731 |
| hazard ratio | 1.4142135623731 |
| thompson jl | 1.4142135623731 |
| effort intolerance | 1.4142135623731 |
| influenza immunization | 1.4142135623731 |
| thiamine deficiency | 1.4142135623731 |
| predetermined threshold | 1.4142135623731 |
| predicted distances | 1.4142135623731 |
| industrialized countries | 1.4142135623731 |
| university of michigan | 1.4142135623731 |
| assmann sf | 1.4142135623731 |
| ellenbogen ka | 1.4142135623731 |
| smoke cigarettes | 1.4142135623731 |
| progressive weakness | 1.4142135623731 |
| gelfman lp | 1.4142135623731 |
| linker dt | 1.4142135623731 |
| bonus payments | 1.4142135623731 |
| pullicino pm | 1.4142135623731 |
| bardy gh | 1.4142135623731 |
| maurer ms | 1.4142135623731 |
| lefkowitz mp | 1.4142135623731 |
| endomyocardial biopsy | 1.4142135623731 |
| gruppo italiano | 1.4142135623731 |
| noncaseating granulomata | 1.4142135623731 |
| ikejiani dz | 1.4142135623731 |
| place chairs | 1.4142135623731 |
| sex-specific equations | 1.4142135623731 |
| repeated transfusions | 1.4142135623731 |
| viable myocardium | 1.4142135623731 |
| reasonable expectation | 1.4142135623731 |
| soliman ez | 1.4142135623731 |
| loeb hs | 1.4142135623731 |
| daniels lb | 1.4142135623731 |
| swollen feet | 1.4142135623731 |
| radionuclide ventriculography | 1.4142135623731 |
| fconnor cm | 1.4142135623731 |
| bull da | 1.4142135623731 |
| euthyroid state | 1.4142135623731 |
| albert nm | 1.4142135623731 |
| speed of absorption | 1.4142135623731 |
| poulin mf | 1.4142135623731 |
| attractive possibility | 1.4142135623731 |
| sutradhar sc | 1.4142135623731 |
| characteristic presentation | 1.4142135623731 |
| shown promise | 1.4142135623731 |
| drazner mh | 1.4142135623731 |
| straight line | 1.4142135623731 |
| blaha mj | 1.4142135623731 |
| mentz rj | 1.4142135623731 |
| cleavage products | 1.4142135623731 |
| journal circulation | 1.4142135623731 |
| voors aa | 1.4142135623731 |
| adams kf | 1.4142135623731 |
| cooper ls | 1.4142135623731 |
| extent of disability | 1.4142135623731 |
| abdominal bloating | 1.4142135623731 |
| chang pp | 1.4142135623731 |
| austin pc | 1.4142135623731 |
| healthy adults | 1.4142135623731 |
| tool kit | 1.4142135623731 |
| dao q | 1.4142135623731 |
| squire ib | 1.4142135623731 |
| prior chemotherapy | 1.4142135623731 |
| whelton pk | 1.4142135623731 |
| nichols ga | 1.4142135623731 |
| dargie hj | 1.4142135623731 |
| birnie dh | 1.4142135623731 |
| future priorities | 1.4142135623731 |
| morrison lk | 1.4142135623731 |
| educational material | 1.4142135623731 |
| self-care guide | 1.4142135623731 |
| lip gy | 1.4142135623731 |
| striated muscles | 1.4142135623731 |
| anorexia nervosa | 1.4142135623731 |
| executive summary | 1.4142135623731 |
| obvious explanation | 1.4142135623731 |
| anker sd | 1.4142135623731 |
| neurohormonal activation | 1.4142135623731 |
| j.jacc .2016.03.605 | 1 |
| .0 b013e31829e8807 | 1 |
| 1.2 ng/ml | 1 |
| 0.8 ng/ml | 1 |
| 2.5 times | 1 |
